Format

Send to

Choose Destination
CNS Oncol. 2014 Nov;3(6):421-31. doi: 10.2217/cns.14.47.

Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.

Author information

1
Department of Oncology, St Jude Children's Research Hospital; 262 Danny Thomas Place, Mail Stop 260, Memphis, TN 38105, USA.

Abstract

Diffuse intrinsic pontine glioma (DIPG) is one of the deadliest pediatric central nervous system cancers in spite of treatment with radiation therapy, the current standard of care. The outcome of affected children remains dismal despite multiple clinical trials that investigated radiation therapy combined with chemotherapy. Recently, multiple genome-wide studies unveiled the distinct molecular characteristics of DIPGs and preclinical models of DIPG were developed to mimic the human disease. Both of these accomplishments have generated tremendous progress in the research of new therapies for children with DIPG. Here we review some of these promising new strategies.

KEYWORDS:

glioma; immunotherapy; pontine; prognosis; targeted; therapy

PMID:
25438813
DOI:
10.2217/cns.14.47
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center